Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F22%3A00357844" target="_blank" >RIV/68407700:21340/22:00357844 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1186/s41181-022-00161-4" target="_blank" >https://doi.org/10.1186/s41181-022-00161-4</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s41181-022-00161-4" target="_blank" >10.1186/s41181-022-00161-4</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology

Popis výsledku v původním jazyce

Background: Recent advances in nanotechnology have ofered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health felds, uses nanoparticles for several applica- tions such as imaging, diagnostic, targeted cancer therapy, drug and gene delivery, tissue engineering, and theranostics. Results: Here, we overview the current state-of-the-art of radiolabeled nanoparticles for molecular imaging and radionuclide therapy. Nanostructured radiopharmaceuticals of technetium-99m, copper-64, lutetium-177, and radium-223 are discussed within the scope of this review article. Conclusion: Nanoradiopharmaceuticals may lead to better development of thera- nostics inspired by ingenious delivery and imaging systems. Cancer nano-theranos- tics have the potential to lead the way to more specifc and individualized cancer treatment. Keywords: Radiolabeled nanoparticles, Technetium-99m, Copper-64, Lutetium-177, Radium-223, Molecular imaging, Radionuclide therapy, Theranostics, Toxicity, Radiopharmacy

Název v anglickém jazyce

Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology

Popis výsledku anglicky

Background: Recent advances in nanotechnology have ofered new hope for cancer detection, prevention, and treatment. Nanomedicine, a term for the application of nanotechnology in medical and health felds, uses nanoparticles for several applica- tions such as imaging, diagnostic, targeted cancer therapy, drug and gene delivery, tissue engineering, and theranostics. Results: Here, we overview the current state-of-the-art of radiolabeled nanoparticles for molecular imaging and radionuclide therapy. Nanostructured radiopharmaceuticals of technetium-99m, copper-64, lutetium-177, and radium-223 are discussed within the scope of this review article. Conclusion: Nanoradiopharmaceuticals may lead to better development of thera- nostics inspired by ingenious delivery and imaging systems. Cancer nano-theranos- tics have the potential to lead the way to more specifc and individualized cancer treatment. Keywords: Radiolabeled nanoparticles, Technetium-99m, Copper-64, Lutetium-177, Radium-223, Molecular imaging, Radionuclide therapy, Theranostics, Toxicity, Radiopharmacy

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EJNMMI Radiopharmacy and Chemistry

ISSN

2365-421X

e-ISSN

2365-421X

Svazek periodika

7

Číslo periodika v rámci svazku

04

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

36

Strana od-do

1-36

Kód UT WoS článku

000787313000001

EID výsledku v databázi Scopus

2-s2.0-85128850047